Your Prescription May Not Be Working—and Substance Use Could Be Why

A patient begins an antidepressant. Weeks pass. The depression does not lift. The prescribing physician, interpreting the absence of response as evidence that the medication is wrong, switches to another agent. That one also fails. The patient is labeled treatment-resistant. A more aggressive medication regimen is initiated. The underlying problem—that the patient's alcohol use is continuously altering how the medication is processed by their body—is never identified.

This sequence is not unusual in dual diagnosis care. It is, in fact, one of the more common pathways by which patients with co-occurring disorders end up on complex, escalating medication regimens that address a pharmacokinetic problem as though it were a diagnostic one. The intersection of substance use and psychiatric drug metabolism is among the most clinically consequential and least discussed topics in dual diagnosis medicine.

How the Body Processes Psychiatric Medications

To understand why substance use disrupts psychiatric medication efficacy, it helps to understand the basic machinery of drug metabolism. The majority of psychiatric medications—antidepressants, antipsychotics, mood stabilizers, anxiolytics—are processed primarily in the liver by a family of enzymes known collectively as the cytochrome P450 system. These enzymes break medications down into metabolites that are then eliminated from the body. The speed at which this process occurs determines how much of an active drug remains in circulation at any given time—what clinicians refer to as the drug's plasma concentration.

Substances of abuse interact with this system in ways that can either accelerate or inhibit the metabolism of psychiatric medications, with clinically significant consequences in either direction.

The Induction Problem: When Substances Speed Metabolism Too Fast

Chronic alcohol use is among the most powerful inducers of the cytochrome P450 enzyme CYP2E1, and it also significantly upregulates CYP3A4—an enzyme responsible for metabolizing a broad range of psychiatric drugs including certain benzodiazepines, some antipsychotics, and several mood stabilizers. When these enzymes are chronically upregulated, the liver clears psychiatric medications from the bloodstream more rapidly than the prescribing physician's dosing assumptions account for.

The clinical result is that a patient taking a standard therapeutic dose of a medication may maintain plasma concentrations far below the therapeutic threshold. The medication appears to be failing. In reality, it is being metabolized too quickly to accumulate to effective levels. If the prescribing clinician is unaware of the patient's alcohol use—which is often the case, given the underreporting that characterizes substance use in clinical settings—the logical response is to increase the dose or change the medication entirely. Neither intervention addresses the root cause.

Chronic tobacco smoking presents a similar but distinct version of this problem. Polycyclic aromatic hydrocarbons in cigarette smoke are potent inducers of CYP1A2, the primary enzyme responsible for metabolizing clozapine and olanzapine, two antipsychotics commonly used in patients with co-occurring psychotic disorders. Smokers require substantially higher doses of these medications to achieve the plasma concentrations that non-smokers reach at standard doses. When a patient who smokes is admitted to a smoke-free inpatient unit, the sudden removal of the CYP1A2 inducer can cause plasma concentrations of these medications to rise sharply—occasionally to toxic levels—within days.

The Inhibition Problem: When Substances Slow Metabolism Dangerously

The opposite dynamic is equally hazardous. Certain substances inhibit cytochrome P450 enzymes rather than inducing them, causing psychiatric medications to accumulate in the bloodstream beyond intended therapeutic levels.

Acute alcohol intoxication, distinct from the chronic use pattern described above, actually inhibits CYP2E1 and CYP3A4 rather than inducing them. This means that a patient who drinks heavily on an occasional basis—rather than continuously—may experience fluctuating medication levels depending on their drinking pattern: subtherapeutic on days of abstinence, potentially supratherapeutic during acute intoxication. The clinical picture this produces—variable mood, inconsistent medication response, periodic side effects—can easily be misread as psychiatric instability.

Cannabis use presents its own pharmacokinetic complexities. THC and CBD both interact with CYP3A4 and CYP2C9, with inhibitory effects that can raise plasma concentrations of certain psychiatric medications. CBD, in particular, is a potent inhibitor of CYP2C19, an enzyme responsible for metabolizing several SSRIs and the antiepileptic drugs sometimes used in mood disorders. As cannabis use becomes more prevalent—and as patients increasingly use CBD products without disclosing this to their prescribers—the potential for unrecognized drug interactions in dual diagnosis populations is growing.

Recovery Itself Changes the Equation

One of the most clinically underappreciated aspects of this problem is that it does not resolve when a patient stops using substances. In the early weeks and months of recovery, the enzyme systems that were induced or inhibited by chronic substance use gradually normalize. This normalization process alters medication metabolism just as significantly as the substance use itself did—but in the opposite direction.

A patient whose antidepressant dose was increased to compensate for alcohol-induced enzyme induction may find, three months into sobriety, that the dose that was barely therapeutic during active use is now producing side effects or toxicity. Conversely, a patient whose medication levels were chronically elevated by enzyme inhibition may experience a recurrence of symptoms as their metabolism normalizes and plasma concentrations fall.

This means that psychiatric medication regimens in dual diagnosis patients are not static clinical decisions. They are dynamic prescriptions that must be revisited at multiple points across the recovery trajectory: during active use, at the point of cessation, during early recovery, and at the point of neurobiological stabilization.

Questions Every Dual Diagnosis Patient Should Ask Their Prescriber

Given the complexity of these interactions, informed self-advocacy is a meaningful clinical tool. The following questions can help patients ensure that their prescribers are accounting for pharmacokinetic variables:

• Does my substance use history affect how my body processes this medication? This question invites the prescriber to engage with the pharmacokinetic dimension of the prescription.

• Will my medication dose need to be adjusted as I move through recovery? This establishes the expectation that the prescription is a dynamic document rather than a fixed one.

• Are there any substances—including alcohol, cannabis, or tobacco—that interact significantly with this medication? Many patients do not realize that tobacco and cannabis carry pharmacokinetic implications comparable to alcohol.

• How will you monitor whether this medication is reaching therapeutic levels in my system? For some medications, therapeutic drug monitoring—measuring plasma concentrations directly—is clinically available and appropriate.

• If this medication doesn't seem to be working, how will we determine whether the problem is the drug itself or how my body is processing it? This question distinguishes between pharmacodynamic failure (the drug is wrong) and pharmacokinetic failure (the drug is not reaching effective levels).

The Prescriber's Responsibility

For clinicians treating dual diagnosis patients, the standard of care demands more than selecting an appropriate psychiatric medication. It requires building a prescribing strategy that accounts for the patient's substance use history, their current stage of recovery, and the known interactions between their substances of use and the enzymes responsible for metabolizing their medications.

This is not a peripheral consideration. In dual diagnosis populations, pharmacokinetic variability is the rule, not the exception. A medication that performs as expected in a patient without a substance use disorder may behave in entirely unpredictable ways in a patient whose hepatic enzyme activity has been chronically altered. Treating that unpredictability as diagnostic information—rather than as a pharmacokinetic signal—is one of the most consequential errors in dual diagnosis care.

The medication may not be failing. The body may simply not be receiving it.